**Abstract**

**Background:** Dopamine level is strictly regulated at the synaptic level because a slight alteration can lead to severe neurological and neuropsychiatric consequences^1^. Dopamine transporter (DAT), which facilitates the reuptake of extracellular dopamine, used to be the sole component of regulating synaptic dopamine level. However, our previous discovery of a direct protein-protein interaction between DAT and presynaptic dopamine D2 receptor (D2R) revealed that this protein complex enables D2R to recruit extra intracellular DAT to the membrane surface and enhance dopamine reuptake^2^. Despite we uncovered this novel target for modulating dopaminergic tone, its effects at the behavioural level remain elusive.

**Methods:** Male Sprague-Dawley rats were used in all three experiments. To examine the effects of D2R-DAT disruption on locomotion, normal rats and dopamine-depleted rats were injected intra-cranially (i.c.v.) with an interfering peptide to disrupt the interaction, and were subsequently placed in 43x43x30 cm open-field chambers to record their voluntary movements. Acute dopamine depletion was induced by two intra-peritoneal injections of α-methyl-p-tyrosine.

In vivo micro-dialysis was also performed in anesthetized rats, starting from the baseline and following after a single S1 injection (i.c.v.). The extracellular level of dopamine in the nucleus accumbens core was determined by high-performance liquid chromatography.

**Results:** The disruption of D2R-DAT complex significantly elevated the voluntary movement in both normal animals and dopamine-depleted animals (*p*\<0.05). The data collected from in vivo micro-dialysis indicated that the disruption of DAT-D2R interaction increased the extracellular dopamine level by approximately 30% compared to baseline.

**Discussion:** The elevation in locomotion and increase in extracellular dopamine together prompted that the D2R-DAT interaction is another valid target site for modulating dopaminergic neurotransmission. More importantly, this study showed that this DAT-D2R protein complex can be a potential therapeutic target for disorders associated with dopamine dysregulation such as Parkinson's disease and attention deficit hyperactivity disorder^3^.
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